Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
Clinical trial NCT03631199 · TERMINATED
Trial details
- NCT number
- NCT03631199
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-21
- Primary completion
- 2021-08-09
- Enrollment
- 673
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.